A new COVID vaccine is scheduled to be released next month, but analysts and health professionals predict that it will likely be met with scepticism even as hospitalizations from “Eris,” a coronavirus variant of the Omicron form, surge across the nation. According to some public health professionals, Americans should embrace the new shot just like they would a flu jab. However, after the vaccine became widely accessible in 2021 and more than 240 million Americans, or 73% of the population, had at least one injection, demand for the vaccine has significantly decreased. Less than 50 million individuals received the doses in the fall of 2022, by which time the majority of people had either the COVID virus or the vaccination. The shot, upgraded to combat the Omicron type of the virus that has been prevalent since last year, will be made available starting next month by healthcare providers and pharmacies like CVS Health (CVS.N) told Reuters. Citing Ashley Kirzinger, director of survey methodology at the Kaiser Family Foundation, Reuters reported that they will be fighting declining fret about the virus as well as exhaustion and doubt about the effectiveness of the vaccination. COVID-19 vaccine manufacturers have reduced their expectations for the immunisation campaign this autumn, and Pfizer, the largest producer of mRNA vaccines with BioNTech, recently warned that, if things don’t go well, it might be necessary to lay off employees. The company’s main rival, Moderna, acknowledged that demand might only be for 50 million doses. Sales of vaccines from Pfizer and Moderna exceeded $56 billion last year; analysts anticipate $20 billion this year.